4//SEC Filing
Quart Barry D 4
Accession 0001384243-25-000004
CIK 0001730430other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 4:38 PM ET
Size
17.7 KB
Accession
0001384243-25-000004
Insider Transaction Report
Form 4
Quart Barry D
Director
Transactions
- Exercise/Conversion
Class A Ordinary Share
2025-12-15$10.36/sh+20,129$208,536→ 32,675 total - Sale
Class A Ordinary Share
2025-12-15$41.51/sh−20,129$835,555→ 12,546 total - Exercise/Conversion
Share Option
2025-12-15−20,129→ 0 totalExercise: $10.36Exp: 2028-02-29→ Class A Ordinary Shares (20,129 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.19 and $41.78. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]The option is fully vested and exercisable.
Documents
Issuer
Kiniksa Pharmaceuticals International, plc
CIK 0001730430
Entity typeother
Related Parties
1- filerCIK 0001384243
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 4:38 PM ET
- Size
- 17.7 KB